Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.

US-based oncology drug developer Artiva Biotherapeutics launched on Friday with $78m in series A funding from investors including GC LabCell, the pharmaceutical company that also provided its cell therapy technology. GC LabCell and sister company GC, the biotech and healthcare holding group formerly known as Green Cross Holdings, joined 5AM Ventures, VenBio Partners and RA…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.